Holen Sie sich die Stockscreener-App
102.78
0.22%
0.225
Handel nachbörslich:
102.00
-0.78
-0.76%
Schlusskurs vom Vortag:
$102.56
Offen:
$103.34
24-Stunden-Volumen:
1.54M
Relative Volume:
0.42
Marktkapitalisierung:
$18.72B
Einnahmen:
$381.03M
Nettoeinkommen (Verlust:
$-1.01B
KGV:
-17.27
EPS:
-5.95
Netto-Cashflow:
$-789.25M
1W Leistung:
+0.87%
1M Leistung:
+0.10%
6M Leistung:
+33.92%
1J Leistung:
+35.29%
1-Tages-Spanne:
$101.77
$103.50
1-Wochen-Bereich:
$100.85
$105.35
52-Wochen-Spanne:
$60.40
$106.83
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
102.78 | 19.35B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
What analysts say about Insmed Incorporated stockBreakthrough stock performance - Autocar Professional
What drives Insmed Incorporated stock pricePowerful market insights - Autocar Professional
Is Insmed Incorporated a good long term investmentOver 200% growth - Autocar Professional
Insmed's Trading Volume Drops 46% to $208 Million Ranking 490th in Market - AInvest
Insmed (INSM) Target Price Raised by Morgan Stanley | INSM Stock News - GuruFocus
Insmed price target raised to $108 from $102 at Morgan Stanley - TipRanks
Insmed (INSM) Price Target Raised to $108 by Morgan Stanley | IN - GuruFocus
What makes Insmed Incorporated stock price move sharplyFree Capital Allocation Plans - beatles.ru
Insmed chief legal officer Smith sells $167,755 in stock By Investing.com - Investing.com Canada
Insmed chair and CEO Lewis sells $699k in shares By Investing.com - Investing.com Canada
Jim Cramer Calls Insmed "Very Speculative" - Yahoo Finance
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Insmed Surges to 292nd in Trading Volume with $31.9 Million Turnover - AInvest
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' - Benzinga
Insmed(INSM.US) Officer Sells US$5.54 Million in Common Stock - 富途牛牛
JPMorgan Elevates Insmed (INSM) Target Price Amid Positive Outlo - GuruFocus
A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts - Nasdaq
RBC Capital Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize
Insmed Incorporated(NasdaqGS: INSM) added to Russell Small Cap Comp Value Index - MarketScreener
Insmed Incorporated: Riding the Russell Reconstitution Wave in Small-Cap Biotech - AInvest
Insmed Surges to 134th in Trading Volume with $612 Million Day Despite Stock Decline - AInvest
Here’s how Insmed grows to be the next $100 billion biotech - statnews.com
Insmed's Insider Sell-Off: Strategic Exit or Buying Opportunity Ahead of Breakthrough Data? - AInvest
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
Russell Rebalance: 3 Stocks Ready to Move Higher - MarketBeat
Insider Sell: Roger Adsett Sells 10,686 Shares of Insmed Inc (INSM) - GuruFocus
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110 - Insider Monkey
10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107 - Insider Monkey
Insmed Trading Volume Plummets 51.8% to $217 Million Ranking 354th in Market Activity - AInvest
Is Insmed Stock Overvalued at $98? - Nasdaq
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating - Insider Monkey
Insmed Completes $750 Million Follow-On Public Offering - Global Legal Chronicle
Is Insmed Stock Overvalued After The 45% Jump? - Forbes
10 Hot Large Cap Stocks to Buy Now - Insider Monkey
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
Insmed Inc (INSM) Soars 30% on Impressive Study - MSN
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results - Insider Monkey
INSM September 19th Options Begin Trading - Nasdaq
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - Yahoo Finance
Insmed (INSM) Soars After Raising $650 million - MSN
Insmed Stock Jumps 29% on Encouraging PAH Study Results - MSN
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com
SEC Form 424B5 filed by Insmed Incorporated - Quantisnow
Insmed prices capital raise of $750 via stock offering - MSN
Insmed announces $650M public offering of common stock - MSN
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):